[1]贾鹏飞,袁 莉,赵利鹏,等.肝移植围术期EPO应用的效果及安全性研究[J].医学信息,2018,31(05):74-77.[doi:10.3969/j.issn.1006-1959.2018.05.024]
　JIA Peng-fei,YUAN Li,ZHAO Li-peng,et al.Study on the Effect and Safety of EPO in Perioperative Period of Liver Transplantation[J].Journal of Medical Information,2018,31(05):74-77.[doi:10.3969/j.issn.1006-1959.2018.05.024]
点击复制

肝移植围术期EPO应用的效果及安全性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年05期
页码:
74-77
栏目:
论著
出版日期:
2018-03-01

文章信息/Info

Title:
Study on the Effect and Safety of EPO in Perioperative Period of Liver Transplantation
文章编号:
1006-1959（2018）05-0074-04
作者:
贾鹏飞1; 袁 莉1; 赵利鹏1; 臧运金2; 薛 欣1
青岛大学附属医院麻醉科1，器官移植科2，山东 青岛 266003
Author(s):
JIA Peng-fei1; YUAN Li1; ZHAO Li-peng1; ZANG Yun-jin2; XUE Xin1
Department of Anesthesiology1,Department of Organ Transplantation2,Affiliated Hospital of Qingdao University,Qingdao 266003,Shandong,China
关键词:
重组人促红细胞生成素; 肝移植; 贫血
Keywords:
Key words：Recombinant human erythropoietin; Liver transplantation; Anemia
分类号:
R656；R619+.1
DOI:
10.3969/j.issn.1006-1959.2018.05.024
文献标志码:
A
摘要:
目的 评价重组人促红细胞生成素在肝移植围术期中的效果及安全性。方法 回顾分析我院2015年9月~2016年12月原位肝移植89例患者的化验检查、用药情况及围术期输血情况，排除二次肝移植手术患者、死亡患者、术中输血＞50 U患者，根据围术期是否应用rHuEPO，分为EPO组和对照组。EPO组入院后根据围术期贫血情况皮下注射 rHuEPO 10000 U/次，1 次/d或1次/2 d；对照组入院后未用rHuEPO。观察两组患者术后血红蛋白、红细胞计数、网织红细胞计数以及输血量的对比情况。结果 ①EPO组患者经治疗后，术后3 d（T1）、术后7 d（T2）、术后15 d（T3）及术后1个月（T4）与术前基础值（T0）比较，Hb变化不大，差异无统计学意义（P＞0.05）；对照组Hb T1、T2、T3、T4与T0比较明显降低，差异有统计学意义（P＜0.01）；EPO组T0时点Hb明显低于对照组，差异有统计学意义（P＜0.01），在T3、T4时点Hb高于对照组，差异有统计学意义（P＜0.05）。②EPO组患者经治疗后，T1、T2、T3、T4与T0比较，RBC计数差异无统计学意义（P＞0.05）；对照组RBC T1、T2、T3、T4与T0比较降低，差异有统计学意义（P＜0.05）；对照组T1、T2、T3、T4时点RBC低于EPO 组，差异有统计学意义（P＜0.05）。③EPO组患者经治疗后，网织红细胞计数（RET）T3、T4时点较对照组明显上升，差异有统计学意义（P＜0.01）； EPO组T3、T4时点与T0比较，RET升高，差异有统计学意义（P＜0.01）；对照组RET 在 T1、T2、T3、T4与T0比较差异无统计学意义（P＞0.05）；组间比较，EPO组T3、T4时点RET 明显高于对照组，差异有统计学意义（P＜0.01）。结论 肝移植贫血患者在围术期皮下注射rHuEPO，术后1个月患者的贫血改善好于对照组，提示rHuEPO对肝移植贫血的重症患者安全、有效。
Abstract:
Abstract：Objective To evaluate the effect and safety of recombinant human erythropoietin(RH)in the perioperative period of liver transplantation.Methods 89 cases of orthotopic liver transplantation from September 2015 to December 2016 in our hospital were retrospectively analyzed,including laboratory examination,drug use and perioperative blood transfusion,excluding secondary liver transplantation patients,dead patients,and patients with intraoperative blood transfusion>50 U.According to whether or not to use rHuEPO during perioperative period,the EPO group and control group.Group EPO was subcutaneously injected with rHuEPO 10000 U/,1 times/d or 1/2 d,and the control group did not use rHuEPO after admission.The comparison of hemoglobin,red blood cell count, reticulocyte count and blood transfusion after operation was observed in the two groups.Results EPO group of patients after treatment, postoperative 3 d(T1),7 d after operation(T2),15 d after operation(T3)and 1 months after surgery(T4)with preoperative value(T0),Hb changed little,there was no statistically significant difference(P>0.05)the control group Hb;T1,T2,T3,T4 and T0 significantly decreased, the difference was statistically significant(P<0.01);EPO group at T0 Hb was significantly lower than the control group,the difference was statistically significant(P<0.01),in T3,T4 at Hb was higher than the control group,the difference was statistically significant(P< 0.05).②EPO group of patients after treatment,T1,T2,T3,T4 and T0,there was no significant difference between RBC count(P>0.05);the control group RBC T1,T2,T3,T4 and T0 decreased,the difference was statistically significant(P<0.05);control group T1,T2,T3,T4 at RBC lower than the EPO group,the difference was statistically significant(P<0.05).③After treatment,the time of reticulocyte count (RET)T3 and T4 in group EPO was significantly higher than that in the control group(P<0.01).Compared with T0 in EPO group,there was a statistically significant increase in RET and RET(P<0.01).There was no significant difference in RET,T1,T2,T3 and T4 between the control group and T0 group(P>0.05).In group comparison,the time point of T3 and T4 in group EPO was significantly higher than that in the control group,and the difference was statistically significant(P<0.01).Conclusion The hypodermic injection of rHuEPO in perioperative period is better than that in the control group at 1 month after operation.It indicates that rHuEPO is safe and effective for severe patients with anemia after liver transplantation.

参考文献/References:

[1]De Santis GC,Brunetta DM,Nardo M,et al.Preoperative variables associated with transfusion requirements in orthotopic liver transplantation[J].TransfusApherSci,2014,50(1):99-105. [2]赵玲莉,耿惠,邓丽君,等.EPO的临床研究进展[J].青海医药杂志,2011,41(3):74-77. [3]张亚芳.促红细胞生成素在危重患者贫血治疗中的效果及安全性探讨[J].华夏医学,2013,26(3):492-494. [4]姚泰.生理学[M].第6版.北京:人民卫生出版社,2004:53.[5]Posluszny Jr JA,Napolitano LM.How do we treat life-threatening anemia in a Jehovah's Witness patient[J].Transfusion,2014,54(12):3026-3034. [6]Garcia JH,Coelho GR,FeitosaNeto BA,et al.Liver transplantation in Jehovah's Witnesses patients in a center of northeastern Brazil[J].ArqGastroenterol,2013,50(2):138-140. [7]de Araujo Azi LM,Lopes FM,Garcia LV.Postoperative management of severe acute anemia in a Jehovah's Witness[J].Transfusion,2014,54(4):1153-1157. [8]Brunetta DM,Kaufman J,DeSantis GC,et al.Severe Acute Anemia After Liver Transplantation in an Elderly Jehovah's Witness Treated With High-dose Erythropoietin and Ferric Carboxymaltose:A Case Report[J].Transplant Proc,2015,47(8):2548-2551. [9]虞德明,白亚强,刘文晶.促红细胞生成素在开颅动脉瘤夹闭术后脑缺血中的应用效果[J].重庆医学,2017,46(3):394-396. [10]朱栩宏,姜飞,杨晶,等.重组人促红细胞生成素及硫酸亚铁在Rh阴性骨盆骨折患者手术中的临床应用价值[J].中华实用诊断与治疗杂志,2017,31(3):284-286. [11]Weltert L,Rondinelli B,Bello R,et al.A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial[J].Transfusion,2015,55(7):1644-1654. [12]朱孔娟,袁莉,董河,等.EPO对脊柱外科病人围术期异体血需求和凝血功能的影响[J].青岛大学医学院学报,2015,51(5):517-520. [13]宋作艳,袁莉,王世端,等.联合应用铁剂和促红细胞生成素对妇科贫血患者异体血需求的影响[J].解放军医学院学报,2014,35(4):316-318. [14]Lund A,Lundby C,Olsen NV.High-dose erythropoietin for tissue protection[J].Eur J Clin Invest， 2014,44(12):1230-1238. [15]Nangaku M.Tissue protection by erythropoietin:new findings in a moving field[J].Kidney Int ，2013,84(3):427-429. [16]Greif F,Ben-Ari Z,Taya R,et al.Dual effect of erythropoietin on liver protection and regeneration after subtotal hepatectomy in rats[J].Liver Transpl,2010,16(5):631-638. [17]Shander A,Javidroozi M,Naqvi S,et al.An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion(CME)[J].Transfusion ，2014，54（10）:2688-2695. [18]Fischer JW.Landmark advances in development of erythropoietin[J].ExpBiolMed,2010,235(12):1398-1411.

相似文献/References:

[1]张运昊.重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的疗效观察[J].医学信息,2019,32(08):151.[doi:10.3969/j.issn.1006-1959.2019.08.046]
　ZHANG Yun-hao.Therapeutic Effect of Recombinant Human Erythropoietin on Chemotherapy-associated Anemia of Gastrointestinal Malignant Tumor[J].Journal of Medical Information,2019,32(05):151.[doi:10.3969/j.issn.1006-1959.2019.08.046]
[2]张 明,刘子荣,李 妍.肝移植患者术后自我管理现状与影响因素分析[J].医学信息,2019,32(14):138.[doi:10.3969/j.issn.1006-1959.2019.14.044]
　ZHANG Ming,LIU Zi-rong,LI yan.Analysis of Self-management Status and Influencing Factors of Postoperative Liver Transplantation Patients[J].Journal of Medical Information,2019,32(05):138.[doi:10.3969/j.issn.1006-1959.2019.14.044]
[3]顾义娟.待肝期精准健康教育对肝癌肝移植患者健康信念及负性情绪的影响[J].医学信息,2020,33(20):170.[doi:10.3969/j.issn.1006-1959.2020.20.054]
　GU Yi-juan.The Impact of Precision Health Education on the Health Beliefs and Negative Emotions of Liver Cancer Patients Undergoing Liver Transplantation[J].Journal of Medical Information,2020,33(05):170.[doi:10.3969/j.issn.1006-1959.2020.20.054]

更新日期/Last Update: 2018-03-01